NKp30 isoforms in patients with chronic hepatitis C virus infection

Immunology

Volumn 146, Issue 2, 2015, Pages 234-242

  Mantovani, Stefania ^a   Mele, Dalila ^a   Oliviero, Barbara ^a   Barbarini, Giorgio ^a   Varchetta, Stefania ^a   Mondelli, Mario U ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Interferon ; Liver fibrosis; Natural killer cells; Unsupervised hierarchical clustering

Indexed keywords

GAMMA INTERFERON; ISOPROTEIN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; NCR3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL FUNCTION; CHRONIC HEPATITIS C; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; FEMALE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRUS REPLICATION; CASE CONTROL STUDY; CELL LINE; CLUSTER ANALYSIS; COCULTURE; COMPLICATION; DISEASE COURSE; GENETIC TRANSFECTION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST PATHOGEN INTERACTION; IMMUNOLOGY; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; PHENOTYPE; PROGNOSIS; SIGNAL TRANSDUCTION; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CELL DEGRANULATION; CELL LINE; CLUSTER ANALYSIS; COCULTURE TECHNIQUES; CYTOKINES; DISEASE PROGRESSION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; KILLER CELLS, NATURAL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; PHENOTYPE; PROGNOSIS; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84941737841     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12495     Document Type: Article

References (29)

1. Lanier LL. Evolutionary struggles between NK cells and viruses. Nat Rev Immunol 2008; 8:259-68.
2. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9:495-502.
3. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23:225-74.
4. Kruse PH, Matta J, Ugolini S, Vivier E. Natural cytotoxicity receptors and their ligands. Immunol Cell Biol 2014; 92:221-9.
5. Oliviero B, Varchetta S, Paudice E et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009; 137:1151-60.
6. Seidel E, Glasner A, Mandelboim O. Virus-mediated inhibition of natural cytotoxicity receptor recognition. Cell Mol Life Sci 2012; 69:3911-20.
7. Vitale M, Della Chiesa M, Carlomagno S et al. NK-dependent DC maturation is mediated by TNFα and IFNγ released upon engagement of the NKp30 triggering receptor. Blood 2005; 106:566-71.
8. Marras F, Bozzano F, Ascierto ML, De Maria A. Baseline and dynamic expression of activating NK cell receptors in the control of chronic viral infections: the paradigm of HIV-1 and HCV. Front Immunol 2014; 5:305.
9. Neville MJ, Campbell RD. A new member of the Ig superfamily and a V-ATPase G subunit are among the predicted products of novel genes close to the TNF locus in the human MHC. J Immunol 1999; 162:4745-54.
10. Delahaye NF, Rusakiewicz S, Martins I et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17:700-7.
11. Semeraro M, Rusakiewicz S, Minard-Colin V et al. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med 2015; 7:283ra55.
12. Prada N, Antoni G, Commo F et al. Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology 2013; 2:e23472.
13. Petta S, Craxì A. Current and future HCV therapy: do we still need other anti-HCV drugs? Liver Int 2015; 35(Suppl 1):4-10.
14. De Maria A, Fogli M, Mazza S et al. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol 2007; 37:445-55.
15. Varchetta S, Mele D, Mantovani S et al. Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. Hepatology 2012; 56:841-9.
16. Nattermann J, Feldmann G, Ahlenstiel G, Langhans B, Sauerbruch T, Spengler U. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 2006; 55:869-77.
17. Bozzano F, Picciotto A, Costa P et al. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. Eur J Immunol 2011; 41:2905-14.
18. Holder K a, Stapleton SN, Gallant ME, Russell RS, Grant MD. Hepatitis C virus-infected cells downregulate NKp30 and inhibit ex vivo NK cell functions. J Immunol 2013; 191:3308-18.
19. Sugden PB, Cameron B, Mina M, Lloyd AR. Protection against hepatitis C infection via NK cells in highly exposed uninfected injecting drug users. J Hepatol 2013; 61:738-45.
20. Ahlenstiel G, Edlich B, Hogdal LJ et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011; 141:1231-9.
21. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000; 31:241-6.
22. T) Method. Methods 2001; 25:402-8.
23. Zhong J, Gastaminza P, Cheng G et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005; 102:9294-9.
24. Kato T, Date T, Murayama A, Morikawa K, Akazawa D, Wakita T. Cell culture and infection system for hepatitis C virus. Nat Protoc 2006; 1:2334-9.
25. Cerino A, Boender P, La Monica N, Rosa C, Habets W, Mondelli MU. A human monoclonal antibody specific for the N terminus of the hepatitis C virus nucleocapsid protein. J Immunol 1993; 151:7005-15.
26. Mondelli MU, Cerino A, Boender P et al. Significance of the immune response to a major, conformational B-cell epitope on the hepatitis C virus NS3 region defined by a human monoclonal antibody. J Virol 1994; 68:4829-36.
27. S terling R, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-25.
28. Vallet-Pichard A, Mallet V, Nalpas B et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatology 2007; 46:32-6.
29. Jarahian M, Fiedler M, Cohnen A et al. Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog 2011; 7:e1002195.